exact

Bill Oxford Shares of Exact Sciences (NASDAQ:EXAS) traded higher on Wednesday after TD Cowen said that the company is seeking a 25% price hike from Medicare for its next-generation colorectal cancer screening test, Cologuard Plus. Analyst Dan Brennan reaffirmed his Buy rating on the stock, arguing that if approved, theContinue Reading